Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection.
Following primary ocular infection, HSV-1 establishes a latent infection in the trigeminal ganglia with the complete absence of detectable infectious virus. Recently, we showed that vaccination of BALB/cJ with HSV-1 glycoprotein K (gK), but not other HSV-1 glycoproteins, significantly exacerbated the severity of HSV-1-induced ocular disease and herpetic dermatitis (H. Ghiasi et al. J. Virol. 68, 2347-2354, 1994). We now report that prior vaccination with gK blocked viral clearance from trigeminal ganglia until at least Day 56 postinfection, resulting in a chronic infection. The significance of this novel finding with respect to potential harmful complications associated with the immune response to gK is discussed.